Early-stage next-gen sequencing company Pacific Biosciences (NASDAQ:PACB)
continues to make progress both with its system specs and its
end-market development, but the path is not smooth or easy. The shares
are still up about 80% from my initial Top Idea write-up, but down about a quarter from my last piece as investors fret over the progress and competitive risks of Illumina (NASDAQ:ILMN), Thermo Fisher (NYSE:TMO), and Oxford Nanopore, as well as questions as to whether the company's development partnership with Roche (OTCQX:RHHBY) will deliver the hoped-for revenue and profits.
Continue here:
Volatile Pacific Biosciences Continues To Make Progress
No comments:
Post a Comment